The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 22 of the 22 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) demonstrated that either intensive lifestyle intervention or metformin could prevent type 2 diabetes in high-risk adults for at least 10 years after randomization. We report the 10-year within-trial cost-effectiveness of the interventions. RESEARCH DESIGN AND METHODS: Data on resource utilization, cost, and quality of life were collected prospectively. Economic analyses were performed from health system and societal perspectives. RESULTS: Over 10 years, the cumulative, undiscounted per capita direct medical costs of the interventions, as implemented during the DPP, were greater for lifestyle ($4,572) than metformin ($2,281) or placebo ($752). The cumulative direct medical costs of care outside the DPP/DPPOS were least for lifestyle ($26,810 lifestyle vs. $27,384 metformin vs. $29,007 placebo). The cumulative, combined total direct medical costs were greatest for lifestyle and least for metformin ($31,382 lifestyle vs. $29,665 metformin vs. $29,759 placebo). The cumulative quality-adjusted life-years (QALYs) accrued over 10 years were greater for lifestyle (6.89) than metformin (6.79) or placebo (6.74). When costs and outcomes were discounted at 3% and adjusted for survival, lifestyle cost $12,878 per QALY, and metformin had slightly lower costs and nearly the same QALYs as placebo. CONCLUSIONS: Over 10 years, from a payer perspective, lifestyle was cost-effective and metformin was marginally cost-saving compared with placebo. Investment in lifestyle and metformin interventions for diabetes prevention in high-risk adults provides good value for the money spent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to potential for type 2 diabetes risk reduction, metformin therapy is also a feasible strategy in real world settings, given its association with cost savings. 15”
From Metformin Prescription Rates for Patients with Prediabetes (2022) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both DPP-modeled intensive lifestyle interventions and individualized MNT for prediabetes have demonstrated costeffectiveness (17,36)”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Does Preventive Care Save Money? Health Economics and the Presidential Candidates
Cohen, J. T., Neumann, P. J., & Weinstein, M. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmp0708558 · Cited by 471 · cited 1×
“Unfortunately, fewer than 1 in 5 new interventions in health and medicine are cost-saving compared with usual care (17).”
BackgroundThe Diabetes Prevention Program Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.1.36 · Cited by 358
Self-citationRenjilian, D. A., Perri, M. G., Nezu, A. M., McKelvey, W. F., Shermer, R. L., & Anton, S. D. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.69.4.717 · Cited by 327 · cited 2×
“Studies have shown that group intervention programs can be as effective as individual programs (12,13).”
BackgroundClinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes
Eddy, D. M., Schlessinger, L., & Kahn, R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00006 · Cited by 318 · cited 2×
“However, one analysis suggested that lifestyle might be too expensive for health plans or a national program to implement (10).”
BackgroundThe Cost to Health Plans of Poor Glycemic Control
Gilmer, T. P., O'Connor, P. J., Manning, W. G., & Rush, W. A. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1847 · Cited by 304
The Direct Medical Cost of Type 2 Diabetes
Brandle, M., Zhou, H., Smith, B. R. K., Marriott, D., Burke, R., Tabaei, B. P., Brown, M. B., & Herman, W. H. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2300 · Cited by 269 · cited 1×
“In 2000, using data from a single managed-care health plan, we estimated that the median, annual, direct medical cost of care for a man with diet-controlled type 2 diabetes with nomicrovascular, neuropathic, or cardiovascular risk factors or complications was approximately $1,700 (23).”
MethodDiabetes Prevention Program Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2518 · Cited by 262
Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.
Caro, J. J., Ward, A. J., & O’Brien, J. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.476 · Cited by 258 · cited 1×
“The costs of diabetes increase with duration of diabetes and with the presence of complications and comorbidities and would be expected to be lower for persons with short durations of diabetes and for those without complications (22).”
BackgroundMedicare and Cost-Effectiveness Analysis
Neumann, P. J., Rosen, A. B., & Weinstein, M. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmsb050564 · Cited by 225
A cost-effectiveness analysis of exercise as a health promotion activity.
Hatziandreu, E. I., Koplan, J. P., Weinstein, M. C., Caspersen, C. J., & Warner, K. E. (1988) · American Journal of Public Health · doi:10.2105/ajph.78.11.1417 · Cited by 193 · cited 1×
“were valued according to whether participants “disliked,” were “neutral,” or “liked” leisure time physical activity (5,14) (Supplementary Table 2).”
BackgroundPalmer, A. J., Roze, S., Valentine, W. J., Spinas, G. A., Shaw, J. E., & Zimmet, P. Z. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90029-x · Cited by 128 · cited 1×
“Although we (7) and others (8,9) suggested that lifestyle would be cost-effective or even cost-saving over the long term, one analysis suggested that it might be too expensive for health plans or a national program to implement (10).”
BackgroundType 2 diabetes: incremental medical care costs during the first 8 years after diagnosis.
Brown, J. B., Nichols, G. A., Glauber, H. S., & Bakst, A. W. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1116 · Cited by 124 · cited 1×
“1 times those of individuals without diabetes, and the incremental cost of diabetes is apparent from the time of diagnosis (20).”
BackgroundBehavior therapy for obesity: A comparative investigation of long-term efficacy.
Kingsley, R. G., & Wilson, G. T. (1977) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.45.2.288 · Cited by 122
Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight and Obese U.S. Adults
Hoerger, T. J., Hicks, K. A., Sorensen, S. W., Herman, W. H., Ratner, R. E., Ackermann, R. T., Zhang, P., & Engelgau, M. M. (2007) · Diabetes Care · doi:10.2337/dc07-0885 · Cited by 112
The Diabetes Prevention Program Research Group, Venditti, E. M., Bray, G. A., Carrion-Petersen, M. L., Delahanty, L. M., Edelstein, S. L., Hamman, R. F., Hoskin, M. A., Knowler, W. C., & Ma., Y. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.134 · Cited by 93
Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada
Caro, J. J., Getsios, D., Caro, I., Klittich, W. S., & O'Brien, J. A. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01330.x · Cited by 67 · cited 1×
“Although we (7) and others (8,9) suggested that lifestyle would be cost-effective or even cost-saving over the long term, one analysis suggested that it might be too expensive for health plans or a national program to implement (10).”
Background
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496
(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
Metadata
- Authors
- The Diabetes Prevention Program Research Group
- Affiliations
- University of Michigan (US)
- Corresponding author
- The Diabetes Prevention Program Research Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-03-13
- Volume
- 35
- Issue
- 4
- Pages
- 723-730
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3308273
- OpenAlex
- W1896651021
- Cited by
- 436
- References
- 22
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 22 · 2023: 19 · 2022: 19 · 2021: 28 · 2020: 38 · 2019: 42 · 2018: 39 · 2017: 43 · 2016: 38 · 2015: 32 · 2014: 29 · 2013: 31 · 2012: 19
- FWCI
- 84.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926, P30DK017047)
- National Center for Research Resources
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes prevention, lifestyle intervention, metformin, cost-effectiveness, Diabetes Prevention Program Outcomes Study, quality-adjusted life years, high-risk adults, direct medical costs, resource utilization (health care), health system perspective, societal perspective
- MeSH terms
- Adult, Combined Modality Therapy, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Prediabetic State, Prognosis, Time Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Reduction Behavior, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.